Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

Medicine & Life Sciences

• Pemetrexed 100%
• Erlotinib Hydrochloride 96%
• Non-Small Cell Lung Carcinoma 67%
• Appointments and Schedules 61%
• Cell Cycle 11%
• Phosphatidylinositol 3-Kinase 9%
• ErbB Receptors 9%
• ras Genes 5%
• thiazolyl blue 5%
• 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5%
• Cell Line 5%
• G1 Phase 4%
• Progression-Free Survival 4%
• Research Design 3%
• Cell Count 3%
• Apoptosis 2%
• Mutation 2%
• Growth 2%
• In Vitro Techniques 2%
• Neoplasms 1%